BIIB: Biogen Inc

BIIB News

• Investing 10:14 Scotiabank downgrades Sage Therapeutics stock rating to Sector Perform
• Investing 14:44 Indivior stock hits 52-week high at $15.52
• Investing 05:49 Barclays upgrades Ionis Pharmaceuticals stock to Overweight on Tryngolza outlook
• Reuters 12:07 INmune Bio's Alzheimer's drug falls short of mid-stage study goal, shares tumble
• Investing 11:48 RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
• Investing 11:37 Biogen begins phase 3 trial of felzartamab for kidney disease
• Seeking Alpha 12:00 S&P 500 Stocks: Screening For Long-Term Winners, My List Of 13 (SPX)
• Investing 11:30 H.C. Wainwright maintains Ionis Pharmaceuticals stock buy rating at $50
• Benzinga 18:53 Biogen/Ionis Drug Shows Promise In Children With Spinal Muscular Atrophy - Ionis Pharmaceuticals (NASDAQ:IONS), Biogen (NASDAQ:BIIB)
• Investing 18:27 RBC sees 40% upside in Biogen as pipeline momentum builds
• Benzinga 17:18 Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday - Carnival (NYSE:CCL), Biogen (NASDAQ:BIIB)
• Investing 11:33 Biogen reports positive interim data for once-yearly SMA treatment
• Investor's Business Daily 11:30 Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
• Investing 06:17 Indivior appoints Tony Kingsley to board of directors
• Seeking Alpha 02:27 Is Biogen A Hidden Gem After 45% Decline (NASDAQ:BIIB)
• Investing 11:35 Biogen initiates phase 3 trial of omaveloxolone for children with FA
• Investing 11:31 Supernus to acquire Sage Therapeutics stock for $8.50 per share
• Investing 14:44 UBS reiterates Biogen stock neutral rating despite recent rally
• Investing 13:59 Supernus stock rating reiterated as Piper Sandler questions Sage deal
• Investing 10:04 Citi initiates Acumen Pharmaceuticals stock with buy rating
• Benzinga 13:45 Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal - Sage Therapeutics (NASDAQ:SAGE), Biogen (NASDAQ:BIIB)
• Investor's Business Daily 13:14 Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics
• Benzinga 15:33 Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results - Biogen (NASDAQ:BIIB)
• Investing 13:01 H.C. Wainwright reiterates Biogen stock buy rating on nephrology potential